Outlook Therapeutics, Inc. (OTLK)
NASDAQ: OTLK · Real-Time Price · USD
1.800
+0.030 (1.69%)
At close: Jun 25, 2025, 4:00 PM
1.853
+0.052 (2.92%)
After-hours: Jun 25, 2025, 7:59 PM EDT
Outlook Therapeutics Stock Forecast
OTLK's stock price has decreased by -75.77% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 5 analysts that cover Outlook Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $9.6, which forecasts a 433.33% increase in the stock price over the next year. The lowest target is $3 and the highest is $21.
Price Target: $9.6 (+433.33%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Outlook Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
Rating | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 |
---|---|---|---|---|---|---|
Strong Buy | 5 | 4 | 4 | 4 | 4 | 4 |
Buy | 0 | 0 | 0 | 0 | 0 | 0 |
Hold | 1 | 1 | 1 | 1 | 1 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 6 | 5 | 5 | 5 | 5 | 5 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
Ascendiant Capital | Ascendiant Capital | Strong Buy Maintains $24 → $21 | Strong Buy | Maintains | $24 → $21 | +1,066.67% | Jun 6, 2025 |
Ascendiant Capital | Ascendiant Capital | Strong Buy Maintains $33 → $24 | Strong Buy | Maintains | $33 → $24 | +1,233.33% | Feb 24, 2025 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $30 → $3 | Strong Buy | Maintains | $30 → $3 | +66.67% | Feb 18, 2025 |
Chardan Capital | Chardan Capital | Hold Maintains $3 | Hold | Maintains | $3 | +66.67% | Feb 18, 2025 |
Guggenheim | Guggenheim | Strong Buy Reiterates $12 | Strong Buy | Reiterates | $12 | +566.67% | Jan 17, 2025 |
Financial Forecast
Revenue This Year
7.43M
Revenue Next Year
35.63M
from 7.43M
Increased by 379.84%
EPS This Year
-1.40
from -4.06
EPS Next Year
-1.13
from -1.40
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | 13.2M | 53.5M | 136.5M | ||
Avg | 7.4M | 35.6M | 116.9M | ||
Low | 1.7M | 16.8M | 95.8M |
Revenue Growth
Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | - | 620.5% | 283.1% | ||
Avg | - | 379.8% | 228.2% | ||
Low | - | 125.7% | 168.8% |
EPS Forecast
EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | -0.76 | -1.00 | 1.32 | ||
Avg | -1.40 | -1.13 | 0.95 | ||
Low | -1.96 | -1.18 | 0.61 |
EPS Growth
EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | - | - | - | ||
Avg | - | - | - | ||
Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.